search
Back to results

Safety and Effectiveness Evaluations of the COLO-BT as an Treatment to the Proctectomy. (COLO-BT)

Primary Purpose

Colorectal Surgery, Colorectal Cancer, Rectal/Anal

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
COLO BT™
Stoma Creation
Sponsored by
JSR Medical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Colorectal Surgery focused on measuring Colorectal Surgery, Colorectal Cancer, Stoma

Eligibility Criteria

19 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: The patient must meet all study Inclusion Criteria as outlined below: Adult males or females, 19-80 years of age, with signed informed consent Subject whose anastomosis is expected to be located above 4cm from the anus, and at or below 15cm from the anus. (4cm < inclusion target ≤ 15cm from the anus). ③ One or more of the following six risk factors for postoperative anastomotic leakage6-8 must be true: - Male - Those with a body mass index of 30 or higher - Current smoker - Those who are on medication for diabetes - Those with clinical stage III or higher malignant tumours - Those who received chemo/radiation therapy before surgery ④ Those who voluntarily decide to participate in this clinical study, read and sign the Informed Consent form, and are willing to comply with the study protocol ⑤ Those who have willingness to undertake blood transfusion if required. Exclusion Criteria: Patients meeting any of the following Exclusion Criteria will not be eligible to participate in the study: Women who are pregnant or breastfeeding Those who receive emergency surgery A person who is expected to need intensive medical care after the surgery due to a serious medical condition, with one or more of the following seven factors being true: Patients with abnormal bone marrow function (those with hemoglobin less than 10g/dl, leukocyte count less than 4000/mm3, or platelet count less than 100,000/mm3 even after preoperative corrections) Patients with severe liver damage or cirrhosis (those whose AST/ALT levels are more than three times the normal range or those diagnosed with cirrhosis) Those with abnormal renal function (those who are on hemodialysis or who have a blood creatinine level of 2.0mg/dl or more before the surgery) Those who have undergone cardiac or cerebrovascular stent procedure within the last 6 months Those who have been diagnosed with pulmonary tuberculosis within the last 6 months or are undergoing drug treatment for pulmonary tuberculosis Those who continuously administer steroids of 20mg/day or more within 30 days before the surgery Patients with ASA (American Society of Anaesthesiologists) score of 3 are evaluated by the investigator who determines whether or not patients with ASA score of 3 should be enrolled from the patient safety standpoint. Patients with ASA score higher than 3 are excluded from this study. Patients who are required to undergo re-intervention to treat the anastomosis following intraoperative positive air leak test (However, patients who underwent complete reconstruction of the anastomosis in the presence of a positive air test, which therefore has made their risk of leak similar to those patients with a negative air leak test.) Patients who are immune suppressed Patients with severe diverticulosis Patients with other colonic wall abnormalities in the likely area of the Outer Balloon and BT BAND application who may be at increased risk for device perforation or migration. ④ A person who has difficulty in mobility or is unable to communicate in general due to a psychiatric/neurologic disorder falling under one or more of the following: Those diagnosed with dementia or Alzheimer's disease. Those who have been diagnosed with schizophrenia or depression or are taking drugs due to this. A person who has been diagnosed with disability due to mental retardation. Patients with intestinal perforation, abscess in the pelvis, or severe inflammation in the pelvis. Those who have a history of undergoing major surgeries (bowel/gastrectomy, hepatectomy, hysterectomy) through laparotomy and are likely to have serious adhesions that may affect this surgery. A patient who underwent a preoperative chemotherapy, but the anastomosis is expected to be located very close to the anus or in the anal canal, thus with a very high risk for complications of the anastomosis, or a patient whom the bowel function is expected to decrease significantly in the future. Patients with inflammatory bowel diseases such as ulcerative colitis, Crohn's disease, intestinal tuberculosis, or autoimmune diseases such as Behcet's disease. ⑨ Those who do not consent in writing to the study. ⑩ Blood loss (>750 cc). ⑪ Transfusion during surgery. ⑫ Any new sign of ischemia. ⑬ Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel, carcinomatosis. ⑭ Exclusion criteria not specified above, but the patient is determined to be unsuitable for participation in this clinical study at the judgment of the researcher.

Sites / Locations

  • Jacobs School of Medicine & Biomedical Sciences, State University of New York at BuffaloRecruiting
  • PennState Health - Milton S. Hershey Medical CenterRecruiting
  • Baylor College of MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

COLO BT™

Standard of Care

Arm Description

Patients receive COLO BT™ during colorectal surgery.

Patients receive the standard of care, a protective stoma, during colorectal surgery.

Outcomes

Primary Outcome Measures

Study Success Case(Avoidance of ostomy)
Study Success Case" is defined as a case which has met both the "Clinical Success" and "Technical Success" requirements throughout the 24 weeks (6 Months) monitoring period, following the initial surgical treatment with COLO-BT™ or temporary ileostomy

Secondary Outcome Measures

Full Information

First Posted
April 12, 2023
Last Updated
September 18, 2023
Sponsor
JSR Medical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05826743
Brief Title
Safety and Effectiveness Evaluations of the COLO-BT as an Treatment to the Proctectomy.
Acronym
COLO-BT
Official Title
Safety and Effectiveness Evaluations of the COLO-BT™ (Colorectal Balloon Tube) as an Alternative Treatment to the Temporary Ileostomy Following Proctectomy.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 4, 2023 (Anticipated)
Primary Completion Date
March 15, 2025 (Anticipated)
Study Completion Date
June 15, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
JSR Medical Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the Colorectal Balloon Tube (hereinafter referred to as COLO-BT™) device, a single use, temporary intraluminal bypass device, intended to reduce contact of fecal content with an anastomotic site, following colorectal surgery (open or laparoscopic)
Detailed Description
A primary diverting stoma is widely used by surgeons in order to bypass low rectal anastomosis and reduce morbidity associated with anastomotic leaks. Typically, a stoma is created for all high-risk patients which mean that many patients are exposed to potentially serious complications associated with the stoma itself without any clinical benefit. COLO BT™ is a local, temporary bypass device that provides protection of the anastomosis and safely postpones stoma. COLO BT™ is designed to avoid stoma creation in all patients except those patients whose anastomoses have not healed after surgery, allowing the others to return to normal activity more quickly and safely.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Surgery, Colorectal Cancer, Rectal/Anal
Keywords
Colorectal Surgery, Colorectal Cancer, Stoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
256 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
COLO BT™
Arm Type
Experimental
Arm Description
Patients receive COLO BT™ during colorectal surgery.
Arm Title
Standard of Care
Arm Type
Active Comparator
Arm Description
Patients receive the standard of care, a protective stoma, during colorectal surgery.
Intervention Type
Device
Intervention Name(s)
COLO BT™
Other Intervention Name(s)
COLO BT
Intervention Description
A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma after surgery for only patients who need it (do not have a healed anastomosis)
Intervention Type
Other
Intervention Name(s)
Stoma Creation
Intervention Description
Protective ileostomy
Primary Outcome Measure Information:
Title
Study Success Case(Avoidance of ostomy)
Description
Study Success Case" is defined as a case which has met both the "Clinical Success" and "Technical Success" requirements throughout the 24 weeks (6 Months) monitoring period, following the initial surgical treatment with COLO-BT™ or temporary ileostomy
Time Frame
24 Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: The patient must meet all study Inclusion Criteria as outlined below: Adult males or females, 19-80 years of age, with signed informed consent Subject whose anastomosis is expected to be located above 4cm from the anus, and at or below 15cm from the anus. (4cm < inclusion target ≤ 15cm from the anus). ③ One or more of the following six risk factors for postoperative anastomotic leakage6-8 must be true: - Male - Those with a body mass index of 30 or higher - Current smoker - Those who are on medication for diabetes - Those with clinical stage III or higher malignant tumours - Those who received chemo/radiation therapy before surgery ④ Those who voluntarily decide to participate in this clinical study, read and sign the Informed Consent form, and are willing to comply with the study protocol ⑤ Those who have willingness to undertake blood transfusion if required. Exclusion Criteria: Patients meeting any of the following Exclusion Criteria will not be eligible to participate in the study: Women who are pregnant or breastfeeding Those who receive emergency surgery A person who is expected to need intensive medical care after the surgery due to a serious medical condition, with one or more of the following seven factors being true: Patients with abnormal bone marrow function (those with hemoglobin less than 10g/dl, leukocyte count less than 4000/mm3, or platelet count less than 100,000/mm3 even after preoperative corrections) Patients with severe liver damage or cirrhosis (those whose AST/ALT levels are more than three times the normal range or those diagnosed with cirrhosis) Those with abnormal renal function (those who are on hemodialysis or who have a blood creatinine level of 2.0mg/dl or more before the surgery) Those who have undergone cardiac or cerebrovascular stent procedure within the last 6 months Those who have been diagnosed with pulmonary tuberculosis within the last 6 months or are undergoing drug treatment for pulmonary tuberculosis Those who continuously administer steroids of 20mg/day or more within 30 days before the surgery Patients with ASA (American Society of Anaesthesiologists) score of 3 are evaluated by the investigator who determines whether or not patients with ASA score of 3 should be enrolled from the patient safety standpoint. Patients with ASA score higher than 3 are excluded from this study. Patients who are required to undergo re-intervention to treat the anastomosis following intraoperative positive air leak test (However, patients who underwent complete reconstruction of the anastomosis in the presence of a positive air test, which therefore has made their risk of leak similar to those patients with a negative air leak test.) Patients who are immune suppressed Patients with severe diverticulosis Patients with other colonic wall abnormalities in the likely area of the Outer Balloon and BT BAND application who may be at increased risk for device perforation or migration. ④ A person who has difficulty in mobility or is unable to communicate in general due to a psychiatric/neurologic disorder falling under one or more of the following: Those diagnosed with dementia or Alzheimer's disease. Those who have been diagnosed with schizophrenia or depression or are taking drugs due to this. A person who has been diagnosed with disability due to mental retardation. Patients with intestinal perforation, abscess in the pelvis, or severe inflammation in the pelvis. Those who have a history of undergoing major surgeries (bowel/gastrectomy, hepatectomy, hysterectomy) through laparotomy and are likely to have serious adhesions that may affect this surgery. A patient who underwent a preoperative chemotherapy, but the anastomosis is expected to be located very close to the anus or in the anal canal, thus with a very high risk for complications of the anastomosis, or a patient whom the bowel function is expected to decrease significantly in the future. Patients with inflammatory bowel diseases such as ulcerative colitis, Crohn's disease, intestinal tuberculosis, or autoimmune diseases such as Behcet's disease. ⑨ Those who do not consent in writing to the study. ⑩ Blood loss (>750 cc). ⑪ Transfusion during surgery. ⑫ Any new sign of ischemia. ⑬ Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel, carcinomatosis. ⑭ Exclusion criteria not specified above, but the patient is determined to be unsuitable for participation in this clinical study at the judgment of the researcher.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kim
Phone
+82-10-9345-1058
Email
jakehykim@jsrmed.co.kr
Facility Information:
Facility Name
Jacobs School of Medicine & Biomedical Sciences, State University of New York at Buffalo
City
Buffalo
State/Province
New York
ZIP/Postal Code
14203
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kim
Phone
716-480-7627
Email
kbrunton@buffalo.edu
Facility Name
PennState Health - Milton S. Hershey Medical Center
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Damaris
Phone
717-531-0003
Ext
268789
Email
dromberger1@pennstatehealth.psu.edu
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hector
Phone
915-271-7135
Email
hector.garcia-chavez@bcm.edu

12. IPD Sharing Statement

Learn more about this trial

Safety and Effectiveness Evaluations of the COLO-BT as an Treatment to the Proctectomy.

We'll reach out to this number within 24 hrs